Companies · Biotechnology

Kineta, Inc.

SEATTLE · Biotechnology

Diligence memoA one-page analyst read on Kineta, Inc. — recommendation, valuation, rhythm, risks.
$87.1M
Total raised · real
18
Rounds
2.0×
Latest step-up
Top 12%
Sector rank · raised
Series B
Latest stage · inferred · Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Kineta, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.28× the median modeled value of Series B Biotechnology companies in 2022–2024 (197 peers) — value vs value, same stage and era.
Dormant
  • Last raise 4.4 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Kineta, Inc. behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
16.5 yr record
Peak capital year was 2017 with $90.4M across 15 filings.
Market position
ahead of 89% of Biotechnology peers
Capital scale is ahead of 89% of Biotechnology peers; modeled value is above 44% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Needs review
Row-level filing totals differ from canonical totals, so amendment/superseded filtering should be checked.
What triggered this
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2017: $90.4M across 15 filings.
  • Largest single filing was $24.4M on 2017-07-01.
  • Filing rows sum to $160.0M, while canonical raised total is $87.1M; likely amendments/superseded rows are mixed into the detail view.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
  • Canonical filtering should be tightened before using row-level totals for diligence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Kineta, Inc. is one of 4291 Biotechnology companies tracked from SEATTLE. By capital raised it ranks in the upper tier (ahead of 89% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2022-02-22
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BPre-Seed · 2009-12-31 Raised $942K (real) Modeled valuation $52M (est)Pre-Seed2009Seed · 2014-06-30 Raised $1.6M (real) Modeled valuation $70M (est)Seed · 2016-06-06 Raised $1.8M (real) Modeled valuation $78M (est)Seed2016Seed · 2017-01-23 Raised $3.3M (real) Modeled valuation $148M (est)Seed · 2017-01-23 Raised $3.3M (real) Modeled valuation $148M (est)Seed2017Pre-Seed · 2017-01-23 Raised $250K (real) Modeled valuation $14M (est)Seed · 2017-02-20 Raised $500K (real) Modeled valuation $22M (est)Seed2017Series B · 2017-07-01 Raised $24M (real) Modeled valuation $967M (est)Series A · 2017-09-01 Raised $5.0M (real) Modeled valuation $181M (est)Series A2017Series B · 2017-09-01 Raised $5.0M (real) Modeled valuation $198M (est)Seed · 2017-09-01 Raised $500K (real) Modeled valuation $22M (est)Seed2017Series A · 2017-09-15 Raised $9.0M (real) Modeled valuation $325M (est)Series B · 2017-09-15 Raised $9.0M (real) Modeled valuation $357M (est)Series B2017Series B · 2017-10-19 Raised $24M (real) Modeled valuation $967M (est)Seed · 2017-11-02 Raised $1.2M (real) Modeled valuation $54M (est)Seed2017Series B · 2017-11-02 Raised $2.5M (real) Modeled valuation $99M (est)Pre-Seed · 2017-11-15 Raised $192K (real) Modeled valuation $11M (est)Pre-Seed2017Series B · 2017-11-15 Raised $1.9M (real) Modeled valuation $75M (est)Series B · 2018-09-13 Raised $7.1M (real) Modeled valuation $280M (est)Series B2018Series B · 2019-04-26 Raised $4.7M (real) Modeled valuation $185M (est)Series B · 2019-10-17 Raised $3.0M (real) Modeled valuation $117M (est)Series B2019Pre-Seed · 2019-10-17 Raised $250K (real) Modeled valuation $14M (est)Seed · 2019-10-17 Raised $3.0M (real) Modeled valuation $131M (est)Seed2019Series B · 2020-06-03 Raised $100K (real) Modeled valuation $4.0M (est)Series A · 2021-05-28 Raised $10M (real) Modeled valuation $233M (est)Series A2021Series B · 2021-05-28 Raised $17M (real) Modeled valuation $468M (est)Series B · 2021-05-28 Raised $16M (real) Modeled valuation $439M (est)Series B2021Series B · 2021-06-29 Raised $1.2M (real) Modeled valuation $31M (est)Series B · 2022-02-22 Raised $2.4M (real) Modeled valuation $47M (est)Series B2022Cumulative $160M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$942K · 2009
Seed$1.6M · 2014
Seed extension$1.8M · 2016
Seed extension$3.3M · 2017
Seed extension$3.3M · 2017
Bridge · Seed-stage$250K · 2017smaller follow-on
Seed extension$500K · 2017
Series B$24.4M · 2017no Series A on file
Bridge · Series B-stage$5.0M · 2017smaller follow-on
Series B extension$5.0M · 2017
Bridge · Series B-stage$500K · 2017smaller follow-on
Bridge · Series B-stage$9.0M · 2017smaller follow-on
Series B extension$9.0M · 2017
Series B extension$24.4M · 2017
Bridge · Series B-stage$1.2M · 2017smaller follow-on
Series B extension$2.5M · 2017
Bridge · Series B-stage$192K · 2017smaller follow-on
Series B extension$1.9M · 2017
Series B extension$7.1M · 2018
Series B extension$4.7M · 2019
Series B extension$3.0M · 2019
Bridge · Series B-stage$250K · 2019smaller follow-on
Bridge · Series B-stage$3.0M · 2019smaller follow-on
Series B extension$100K · 2020
Bridge · Series B-stage$10.0M · 2021smaller follow-on
Series B extension$17.4M · 2021
Series B extension$16.3M · 2021
Series B extension$1.2M · 2021
Series B extension$2.4M · 2022

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$47.0M
Base estimate est.
$4.8M
Conservative case
$131.9M
Upside case
$13.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $52.0M · 2009-12-312009Seed · modeled $69.5M · 2014-06-30Seed · modeled $77.8M · 2016-06-06Seed · modeled $147.9M · 2017-01-23Seed · modeled $147.9M · 2017-01-23Pre-Seed · modeled $13.8M · 2017-01-23Seed · modeled $22.2M · 2017-02-20Series B · modeled $967.2M · 2017-07-01Series A · modeled $180.8M · 2017-09-01Series B · modeled $198.4M · 2017-09-01Seed · modeled $22.2M · 2017-09-01Series A · modeled $325.4M · 2017-09-15Series B · modeled $357.2M · 2017-09-15Series B · modeled $967.2M · 2017-10-19Seed · modeled $54.0M · 2017-11-02Series B · modeled $99.1M · 2017-11-02Pre-Seed · modeled $10.6M · 2017-11-15Series B · modeled $74.6M · 2017-11-15Series B · modeled $280.2M · 2018-09-13Series B · modeled $184.6M · 2019-04-26Series B · modeled $117.1M · 2019-10-17Pre-Seed · modeled $13.8M · 2019-10-17Seed · modeled $131.0M · 2019-10-17Series B · modeled $4.0M · 2020-06-03Series A · modeled $233.3M · 2021-05-28Series B · modeled $467.7M · 2021-05-28Series B · modeled $439.3M · 2021-05-28Series B · modeled $30.6M · 2021-06-29Series B · modeled $47.0M · 2022-02-222022
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
4.3 yr
Elapsed time used
4.3 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
5 mo
Avg between rounds
$7.2M/yr
Capital velocity
16.5 yr
On record since
2009
First round
29
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 12× above median
This company$87.1M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.1× of median
This company$2.4M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 0.7× of median
This company$47.0M
Sector median$64.2M

Raised more than 89% of sector peers (real $). Modeled value above 44% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #163 of 197.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0M$100.0M$1.0BCapital raised (log)Mt McKinley Medical Holding Corp USA · Series B Raised $40.0M · modeled $737.5M (est)YAP Therapeutics Inc · Series B Raised $30.1M · modeled $617.6M (est)Pinteon Therapeutics, Inc. · Series B Raised $39.2M · modeled $603.1M (est)OncXerna Therapeutics, Ltd. · Series B Raised $30.0M · modeled $590.7M (est)EpiBiologics, Inc. · Series B Raised $30.0M · modeled $569.5M (est)GIOGI Ltd · Series B Raised $27.3M · modeled $553.9M (est)SonoThera, Inc. · Series B Raised $30.4M · modeled $550.2M (est)Perceive Biotherapeutics, Inc. · Series B Raised $40.0M · modeled $544.0M (est)GIOHEALTH Ltd · Series B Raised $24.5M · modeled $498.0M (est)GIOCAN Ltd · Series B Raised $24.5M · modeled $498.0M (est)GIODIA Ltd · Series B Raised $24.5M · modeled $498.0M (est)Cerapedics Inc · Series B Raised $99.1M · modeled $491.7M (est)Kineta, Inc. (this company) Raised $87.1M · modeled $47.0M (est)Kineta, Inc.
CompanyStageRaised · realValue · estvs peer med.
Mt McKinley Medical Holding Corp USASeries B$40.0M$737.5M4.41×
YAP Therapeutics IncSeries B$30.1M$617.6M3.69×
Pinteon Therapeutics, Inc.Series B$39.2M$603.1M3.60×
OncXerna Therapeutics, Ltd.Series B$30.0M$590.7M3.53×
EpiBiologics, Inc.Series B$30.0M$569.5M3.40×
GIOGI LtdSeries B$27.3M$553.9M3.31×
SonoThera, Inc.Series B$30.4M$550.2M3.29×
Perceive Biotherapeutics, Inc.Series B$40.0M$544.0M3.25×
GIOHEALTH LtdSeries B$24.5M$498.0M2.97×
GIOCAN LtdSeries B$24.5M$498.0M2.97×
GIODIA LtdSeries B$24.5M$498.0M2.97×
Cerapedics IncSeries B$99.1M$491.7M2.94×
Kineta, Inc. this companySeries B$87.1M$47.0M0.28×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$942K2009-12-31$5.2M$52.0M85%
Seed$1.6M2014-06-30$7.8M$69.5M85%
Seed$1.8M2016-06-06$8.8M$77.8M85%
Seed$3.3M2017-01-23$16.7M$147.9M90%
Seed$3.3M2017-01-23$16.7M$147.9M90%
Pre-Seed$250K2017-01-23$1.4M$13.8M90%
Seed$500K2017-02-20$2.5M$22.2M90%
Series B$24.4M2017-07-01$135.4M$967.2M90%
Series A$5.0M2017-09-01$22.7M$180.8M90%
Series B$5.0M2017-09-01$27.8M$198.4M90%
Seed$500K2017-09-01$2.5M$22.2M90%
Series A$9.0M2017-09-15$40.9M$325.4M90%
Series B$9.0M2017-09-15$50.0M$357.2M90%
Series B$24.4M2017-10-19$135.4M$967.2M90%
Seed$1.2M2017-11-02$6.1M$54.0M90%
Series B$2.5M2017-11-02$13.9M$99.1M90%
Pre-Seed$192K2017-11-15$1.1M$10.6M90%
Series B$1.9M2017-11-15$10.4M$74.6M90%
Series B$7.1M2018-09-13$39.2M$280.2M90%
Series B$4.7M2019-04-26$25.8M$184.6M90%
Series B$3.0M2019-10-17$16.4M$117.1M90%
Pre-Seed$250K2019-10-17$1.4M$13.8M90%
Seed$3.0M2019-10-17$14.8M$131.0M90%
Series B$100K2020-06-03$556K$4.0M90%
Series A$10.0M2021-05-28$45.5M$233.3M90%
Series B$17.4M2021-05-28$96.7M$467.7M90%
Series B$16.3M2021-05-28$90.8M$439.3M90%
Series B$1.2M2021-06-29$6.6M$30.6M90%
Series B$2.4M2022-02-22$13.3M$47.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$942K2009-12-31
    • First recorded raise — entered as Pre-Seed.
    • 25 investors on this round.
  2. Seed$1.6M2014-06-30
    • Raised again after 54 mo — slower than the ~14 mo sector norm.
    • Round 1.7× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 06).
    • 6 investors on this round.
  3. Seed$1.8M2016-06-06
    • Raised again after 23 mo — slower than the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 20 investors on this round.
  4. Seed$3.3M2017-01-23
    • Came back fast: 8 mo vs the ~14 mo sector norm.
    • Round 1.9× larger than the prior — scaling up.
    • 21 investors on this round.
  5. Seed$3.3M2017-01-23
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 21 investors on this round.
  6. Pre-Seed$250K2017-01-23
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 13.3× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  7. Seed$500K2017-02-20
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round 2.0× larger than the prior — scaling up.
    • 1 investor on this round.
  8. Series B$24.4M2017-07-01
    • Came back fast: 4 mo vs the ~14 mo sector norm.
    • Round 48.7× larger than the prior — scaling up.
  9. Series A$5.0M2017-09-01
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 4.9× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  10. Series B$5.0M2017-09-01
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  11. Seed$500K2017-09-01
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 10.0× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  12. Series A$9.0M2017-09-15
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 18.0× larger than the prior — scaling up.
    • 1 investor on this round.
  13. Series B$9.0M2017-09-15
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 2 investors on this round.
  14. Series B$24.4M2017-10-19
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round 2.7× larger than the prior — scaling up.
    • 182 investors on this round.
  15. Seed$1.2M2017-11-02
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 20.1× smaller than the prior — bridge or down round.
    • 15 investors on this round.
  16. Series B$2.5M2017-11-02
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.1× larger than the prior — scaling up.
    • 22 investors on this round.
  17. Pre-Seed$192K2017-11-15
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 13.0× smaller than the prior — bridge or down round.
    • 3 investors on this round.
  18. Series B$1.9M2017-11-15
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 9.8× larger than the prior — scaling up.
    • 46 investors on this round.
  19. Series B$7.1M2018-09-13
    • Raised 10 mo later, in step with the ~14 mo sector norm.
    • Round 3.8× larger than the prior — scaling up.
    • 134 investors on this round.
  20. Series B$4.7M2019-04-26
    • Came back fast: 7 mo vs the ~14 mo sector norm.
    • Round 1.5× smaller than the prior — bridge or down round.
    • 43 investors on this round.
  21. Series B$3.0M2019-10-17
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round 1.6× smaller than the prior — bridge or down round.
    • 9 investors on this round.
  22. Pre-Seed$250K2019-10-17
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 11.8× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  23. Seed$3.0M2019-10-17
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 11.8× larger than the prior — scaling up.
    • 9 investors on this round.
  24. Series B$100K2020-06-03
    • Came back fast: 8 mo vs the ~14 mo sector norm.
    • Round 29.5× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  25. Series A$10.0M2021-05-28
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 100.0× larger than the prior — scaling up.
    • 1 investor on this round.
  26. Series B$17.4M2021-05-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.7× larger than the prior — scaling up.
    • 19 investors on this round.
  27. Series B$16.3M2021-05-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 10 investors on this round.
  28. Series B$1.2M2021-06-29
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round 13.8× smaller than the prior — bridge or down round.
    • 11 investors on this round.
  29. Series B$2.4M2022-02-22
    • Came back fast: 8 mo vs the ~14 mo sector norm.
    • Round 2.0× larger than the prior — scaling up.
    • 1 investor on this round.
Intelligence
2022 ~Q3
Modeled next raise · ~5mo cadence
$4.9M
Modeled next size est.range $3.2M$7.8M
2.0×
Last step-up
$7.2M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Charles Magness3 other2009-12
Marion R Foote3 other2017-01
Michael Banks3 other2017-11
Shawn Iadonato3 other2009-12
Charles L Magness2 other2014-06
Marion Foote2 other2017-11
Raymond Bartoszek2 other2017-11
Steven R. Mitchell2 other2017-01
Craig Philips1 other2017-01
Raymond R. Bartoszek1 other2017-01
Richard Samuelson1 other2017-11
Robert Hedequist1 other2016-06
Campion Fellin2009-12
Don Merlino2017-11
Don R. Merlino2017-01
Jiyoung R. Hwang2021-05
Kenneth North2009-12
Kevin Oh2021-06
Kyungwon R. Oh2021-05
Lucien Fouke III2009-12
Michael R. Banks2017-01
Pauline Kenny2016-06
Richard R. Samuelson2017-01
Shawn Ladonato2019-10
Registry & provenance

Kineta, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1479365
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Kineta, Inc./DeBiotechnologySeries C$141.6M$34.2Mnetwork4 shared operators · same sector
Kv1.3 Therapeutics, Inc.BiotechnologyPre-Seed$168K$9.3Mnetwork3 shared operators · same sector
Kineta One, LLCBiotechnologySeries A$7.4M$4.5Mnetwork2 shared operators · same sector
Kineta Holdings II, LLCBiotechnologySeed$2.1M$61.0Mnetwork2 shared operators · same sector
Second Heart Assist, Inc.BiotechnologySeries B$84.3M$39.7Msame sector · same stage
Opgen IncBiotechnologySeries B$81.0M$50.9Msame sector · same stage
NeuroBo Pharmaceuticals, Inc.BiotechnologySeries B$93.9M$49.4Msame sector · same stage
Longeveron Inc.BiotechnologySeries B$79.7M$54.8Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Kineta, Inc./DeBiotechnologySeries C$34.2M98%
Kineta Immuno-Oncology, LLCBiotechnologyPre-Seed$13.2M89%
Kiniksa Pharmaceuticals, Ltd.BiotechnologySeries A$318.1M89%
Metsera, Inc.BiotechnologySeries D+$2.1B87%
KinaRX, LLCBiotechnologyPre-Seed$7.2M87%
Mitera Biosciences Inc.BiotechnologySeed$9.4M86%
Vineti, Inc.BiotechnologySeries C$2.8B85%
Syncromune, Inc.BiotechnologySeries C$385.3M84%
Frequently asked
How much funding has Kineta, Inc. raised?
Kineta, Inc. has raised approximately $87.1M in disclosed capital across 18 recorded financing rounds, aggregated from public filings.
What is Kineta, Inc.'s estimated valuation?
Provath's modeled valuation for Kineta, Inc. is approximately $47.0M (modeled range $4.8M–$131.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Kineta, Inc. at?
Kineta, Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Tue Feb 22.
What does Kineta, Inc. do and where is it based?
Kineta, Inc. operates in the Biotechnology sector, based in SEATTLE.
Explore related

See where Kineta, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Kineta, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.